Five years after Novartis made history with the approval of the first CAR-T, Kymriah, we’re getting a clearer picture of just how important the advance was for some patients. The pharma giant may still be having trouble manufacturing the treatment or reaching long-cherished goals of blockbuster revenue, but a new study shows that its positive … Continue reading Novartis may still be grappling with Kymriah sales, but historic CAR-T promise still shines through 5-year data